Companies: 10,795·Total market cap: $144.5T
Nektar Therapeutics

Nektar Therapeutics

NKTRNASDAQHealthcare● Active
$56.24
$-1.09(-1.89%)
Market Cap$1.1B
P/E Ratio—
52W High$109
52W Low$7.99
SEC Filings

Nektar Therapeutics (NKTR) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0000906709 · NKTR · NASDAQ · as of Jun 8, 2026

Filing snapshot

1,004+
Total Filings
8-K
Latest Form
2026-06-05
Most Recent
1994
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0000906709 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-13
Fiscal Year End
Mar 13, 2026
Accession No.
0001193125-26-104547
Primary Document
nktr-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0000906709 · Accession 0001193125-26-104547

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-08
View 10-Q on SEC
8-KCurrent Report
CURRENT REPORT
2026-06-05Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
CURRENT REPORT
2026-06-05
View
3Initial Statement of Beneficial Ownership
3
2026-05-26
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
424B5424B5
424B5
2026-05-08
View
8-KCurrent Report
8-K
2026-05-08
View
10-QQuarterly Report
10-Q
2026-05-08
View
8-KCurrent Report
CURRENT REPORT
2026-05-07
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-06
View
ARSARS
ARS
2026-04-24
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-24
View
DEF 14AProxy Statement
DEF 14A
2026-04-24
View
8-KCurrent Report
8-K
2026-04-23
View
424B5424B5
424B5
2026-04-23
View
424B5424B5
424B5
2026-04-20
View
8-KCurrent Report
8-K
2026-04-20
View
Showing 1–15 of 409 filingsForm 4 / 144 hidden· 1004 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0000906709  |  Exchange: NASDAQ · Healthcare

Nektar Therapeutics (NASDAQ: NKTR) has submitted 1,004+ documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 1994. As a Healthcare sector company with CIK 0000906709, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Nektar Therapeutics's most comprehensive regulatory disclosure. The most recent Nektar Therapeutics 10-K was filed on 2026-03-13 for fiscal year ending 2026. Historical NKTR 10-K annual reports are available from 2014 through 2026.

Investors researching Nektar Therapeutics SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
RLAY SEC Filings →ELVN SEC Filings →SNDX SEC Filings →ATAI SEC Filings →INBX SEC Filings →IMTX SEC Filings →AMLX SEC Filings →XNCR SEC Filings →
→ NKTR Financials→ NKTR Earnings→ NKTR Insider Trades

Frequently Asked Questions

NKTR SEC Filings · 8 questions

Nektar Therapeutics (NKTR) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 1,004+ filings and access original documents at no cost. Nektar Therapeutics's CIK is 0000906709.

NKTR SEC filingsNektar Therapeutics SEC documentsfind NKTR 10-K